Search
for
Sort by
Research 361–390 of 1000+
- Characterizing Lipid Changes and Use of Lipid-Lowering Medications in Patients With Alopecia Areata Treated With Baricitinib: Integrated Results From the BRAVE-AA1 and -AA2 Clinical Trials
- Treatment of Alopecia Areata and Its Numerous Possibilities: A Literature Review
- Alopecia universalis with IL-12-RB1 and STAT4 mutations effectively treated with upadacitinib
- Editorial: Targeted immunological therapies in dermatology
- Novel investigational drugs for alopecia areata and future perspectives
- Alopecia areata: Time for position statement to include new systemic therapeutic advances
- Treatment of lichen planopilaris with Janus kinase inhibitors
- Effectiveness of oral tofacitinib treatment on patients with moderate‐to‐severe alopecia areata in Iran
- 26 Characterization of a murine model of aa induced by adoptive transfer of cultured lymph node cells
- 44182 Treatment with Oral Janus Kinase Inhibitors in Adults Patients with Alopecia Areata: A Systematic Review and Meta-Analysis
- Combination of baricitinib and conventional immunomodulating therapy for alopecia totalis
- BH09 Patient experience of off-label Janus kinase inhibitor use for alopecia areata in a cohort of 34 patients from a single UK practitioner: exploring changing trends in healthcare provision and access to drug treatments
- Citrullination at the Inflammatory Skin Barrier
- Systemic immunotherapies
- ISID1108 - Comparison of ruxolitinib and a collagen-targeted PTH-based hair cycle stimulant on hair follicle counts and hair growth in the C3H/HeJ engrafted mouse model of alopecia areata.
- 1332 Janus kinase inhibitor increases hair growth by increasing beta-catenin activity in outer root sheath cells
- Janus kinase inhibitor as a therapeutic option in alopecia areata. Case report
- Analyzing the role of tofacitinib in treatment of alopecia areata: A retrospective analysis from a tertiary care center of North India
- 026 Targeting pathogenic MICA-NKG2D interactions by statins: A novel adjunct treatment strategy for alopecia areata management?
- USE OF TOFACITINIB IN DIFFICULT TO TREAT CLINICALLY AMYOPATHIC DERMATOMYOSITIS
- 32237 Clinician and patient evaluation of improvement for eyebrow and eyelashes hair loss during baricitinib phase 3 trials BRAVE-AA1 and BRAVE-AA2
- Alopecia Areata, triggered by psychological stress and successfully treated with a Janus kinase inhibitor. Case report
- 056 IL-15 prolongs hair growth and operates as a guardian of human hair follicle immune privilege
- A retrospective review of paediatric alopecia areata cases seen in a tertiary institution in Singapore
- Janus Kinase Inhibitors - A next generation treatment in Dermatology
- 66-Year-Old Female with Itchy Scalp and Hair Loss
- DataSheet2_Vitiligo: An Autoimmune Skin Disease and its Immunomodulatory Therapeutic Intervention.PDF
- LB789 Novel IFNγ aptamer TAGX-0003 protected hair follicles from immune privilege collapse and reversed Alopecia Areata like phenotype in humanized mouse model
- Inhibidor janus kinasa como opción terapéutica en alopecia areata. Reporte de caso
- Use of intramuscular triamcinolone acetonide in intermediate responders to janus kinase inhibition for alopecia areata: Case report